B. Riley Downgrades Enovix Following Q3 Results
Following Enovix Corporation's third-quarter 2026 results and the subsequent disclosure of revised strategic priorities, B. Riley downgraded the company's stock from buy to neutral. The firm also lowered its price target for Enovix from $9 to $2. This analyst action follows the company's report of $11.04 million in revenue and the announcement of fourth-quarter revenue guidance that fell below analyst consensus expectations.